Opinion|Videos|October 14, 2024
Optimizing Vitiligo Management: Key Takeaways on Treatment Cycling and Ruxolitinib Use
Author(s)Terry Faleye, MPAS, PA-C
Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
5